Overview

Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of the early administration of somatostatin in infusion during 72 hours plus 2 boluses, compared to placebo in the control of acute severe UGIB with suspicion of PUB.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Pharma
Treatments:
Somatostatin